Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN016 combination therapy in unresectable locally advanced or metastatic HER2-negative breast cancer
CTR20251595Phase 2Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JSKN016 in breast cancer, sponsored by Kanion Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
JSKN016
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20251595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251595.